{"id":512,"date":"2015-06-03T01:39:21","date_gmt":"2015-06-03T01:39:21","guid":{"rendered":"https:\/\/blogs.bmj.com\/jnnp\/?p=512"},"modified":"2015-06-03T01:39:21","modified_gmt":"2015-06-03T01:39:21","slug":"amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/","title":{"rendered":"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics"},"content":{"rendered":"

For most clinicians, having to tell a patient that they have motor neuron disease\/amyotrophic lateral sclerosis (ALS) is a difficult and challenging dilemma. In the community, it is one of the few remaining conditions that are inseparably linked with severe physical disability resulting in loss of independence and eventually loss of life. On a more optimistic note, the pace of research in this field provides hope for a cure or at the least for treatments that may slow the progression of the condition.<\/p>\n

ALS was first described by Jean-Martin Charcot, the father of modern Neurology and in the current issue of JNNP, Turner and Swash http:\/\/jnnp.bmj.com\/content\/86\/6\/667.abstract<\/a> chart the historical journey that commenced with Charcot\u2019s initial descriptions of the condition, which largely remain true and accurate to the present day. In addition, the authors have also managed to provide a state-of-the-art review of where we are at in terms of genetic contributions to this condition and provide a thorough analysis on the potential cause of ALS.<\/p>\n

In addition to the obvious question of who is likely to develop ALS, they also touch on another intriguing question of whether there are individuals who are likely to never<\/strong> <\/em>develop ALS.<\/p>\n

In short, this is a highly recommended review.<\/p>\n","protected":false},"excerpt":{"rendered":"

For most clinicians, having to tell a patient that they have motor neuron disease\/amyotrophic lateral sclerosis (ALS) is a difficult and challenging dilemma. In the community, it is one of the few remaining conditions that are inseparably linked with severe physical disability resulting in loss of independence and eventually loss of life. On a more […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":161,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-512","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nAmyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics - JNNP blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics - JNNP blog\" \/>\n<meta property=\"og:description\" content=\"For most clinicians, having to tell a patient that they have motor neuron disease\/amyotrophic lateral sclerosis (ALS) is a difficult and challenging dilemma. In the community, it is one of the few remaining conditions that are inseparably linked with severe physical disability resulting in loss of independence and eventually loss of life. On a more [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/\" \/>\n<meta property=\"og:site_name\" content=\"JNNP blog\" \/>\n<meta property=\"article:published_time\" content=\"2015-06-03T01:39:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics\",\"datePublished\":\"2015-06-03T01:39:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/\"},\"wordCount\":222,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/\",\"name\":\"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics - JNNP blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\"},\"datePublished\":\"2015-06-03T01:39:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2015\\\/06\\\/03\\\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"name\":\"JNNP blog\",\"description\":\"The official JNNP blog. A place to discuss wider neurology beyond the journal's monthly edition.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\",\"name\":\"JNNP blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"width\":427,\"height\":34,\"caption\":\"JNNP blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics - JNNP blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/","og_locale":"en_US","og_type":"article","og_title":"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics - JNNP blog","og_description":"For most clinicians, having to tell a patient that they have motor neuron disease\/amyotrophic lateral sclerosis (ALS) is a difficult and challenging dilemma. In the community, it is one of the few remaining conditions that are inseparably linked with severe physical disability resulting in loss of independence and eventually loss of life. On a more [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/","og_site_name":"JNNP blog","article_published_time":"2015-06-03T01:39:21+00:00","twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/"},"author":{"name":"","@id":""},"headline":"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics","datePublished":"2015-06-03T01:39:21+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/"},"wordCount":222,"commentCount":1,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/","url":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/","name":"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics - JNNP blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#website"},"datePublished":"2015-06-03T01:39:21+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jnnp\/2015\/06\/03\/amyotrophic-lateral-sclerosis-from-charcot-to-cutting-edge-molecular-genetics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jnnp\/"},{"@type":"ListItem","position":2,"name":"Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jnnp\/#website","url":"https:\/\/blogs.bmj.com\/jnnp\/","name":"JNNP blog","description":"The official JNNP blog. A place to discuss wider neurology beyond the journal's monthly edition.","publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jnnp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization","name":"JNNP blog","url":"https:\/\/blogs.bmj.com\/jnnp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","contentUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","width":427,"height":34,"caption":"JNNP blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/jnnp\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/users\/161"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/comments?post=512"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/512\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media?parent=512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/categories?post=512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/tags?post=512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}